Drug Profile
Research programme: allergy vaccines - Anergis
Alternative Names: AllerDM; AllerDM dust mites - Anergis; AllerG; AllerG grass - Anergis; AllerJ; AllerJ Japanese cedar - Anergis; AllerR; AllerR ragweed - Anergis; Bet v 1 COP-virosomes; COP allergen immunotherapy - Anergis; Der p 2 COPsLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator University of Lausanne
- Developer Anergis; Mymetics Corporation
- Class Allergy immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bee venom hypersensitivity; Grass pollen hypersensitivity; Hypersensitivity; Ragweed pollen hypersensitivity; Tree pollen hypersensitivity
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Allergy(Prevention) in Switzerland (SC, Injection)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Ragweed pollen hypersensitivity(Prevention) in Switzerland (SC, Injection)
- 28 May 2022 No recent reports of development identified for research development in Allergy(Prevention) in Switzerland (Parenteral)